Jefferies reiterates Buy on Stryker stock, keeps $465 target

NodeGuardian · 2026-03-07T04:23:51+00:00

Jefferies maintained a "Buy" rating on Stryker Corp. with a $465 price target, despite concerns of overvaluation. The company's robust fundamentals, strong Q4 earnings, and a new robotic system release support its growth outlook.

NodeGuardian

2026-03-07 04:23:51

Abstract generation in progress

Jefferies has reiterated a “Buy” rating on Stryker Corp. (NYSE:SYK) and maintained a $465.00 price target, despite InvestingPro analysis suggesting the stock may be overvalued. The medical technology company’s management expressed confidence in its long-term growth, supported by strong fundamentals and a diversified portfolio. Recent news also noted strong Q4 2025 earnings, a dividend increase, and the limited market release of the Mako RPS robotic system.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.